• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.
【24h】

Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.

机译：急性加重性精神分裂症患者的人口统计学，利培酮剂量和临床结局对体重的影响。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Predictors for risperidone-related weight gain remain unclear. This study aimed to identify clinical factors influencing body weight in risperidone-treated patients. METHOD: One hundred forty-six newly hospitalized DSM-IV schizophrenia patients with acute exacerbation entered this prospective, 6-week, repeated-measures trial. The mean +/- SD risperidone dose was 4.3 +/- 1.4 mg/day at week 6. Efficacy, body weight, and tolerability were measured biweekly. Efficacy was assessed with the Positive and Negative Syndrome Scale (PANSS) and the Nurses' Observation Scale for Inpatient Evaluation (NOSIE). For determining the impacts of possible prognostic factors on body weight, we utilized generalized estimating equation methods to control for other variables and the within-subject dependence over repeated assessments. RESULTS: After the effects of other factors (including baseline body weight) were adjusted, every 1-week increase in treatment duration raised body weight by 0.442 kg (p <.0001). Increasing baseline body weight by 1 kg reduced weight gain by 0.022 kg (p <.0001). Every 1-year increment in age decreased body weight by 0.052 kg (p <.001). Undifferentiated subtype predicted higher weight by around 0.9 kg than other sub-types (p <.05). Each 1-mg/day increment in risperidone dosage heightened body weight by 0.084 kg (p =.015). Responders (those with PANSS total-score reduction > or = 20%) also had higher weight by 0.513 kg on average (p =.007). Specifically, every 1-point diminution in score in PANSS total, PANSS positive, PANSS negative, PANSS cognitive, and NOSIE increased body weight, on average, by 0.029 kg, 0.057 kg, 0.079 kg, 0.079 kg, and 0.035 kg, respectively (p < or =.009). Other variables did not have significant influences. CONCLUSION: The results suggest that lower initial body weight, younger age, undifferentiated subtype, higher dosage, and treatment response (for positive, negative, and cognitive symptoms and social functioning) are associated with greater weight gain in acutely ill patients treated with risperidone. Further studies with longer observation and in other populations are needed.
机译：背景：与利培酮相关的体重增加的预测因素仍不清楚。这项研究旨在确定影响利培酮治疗患者体重的临床因素。方法：146例新近住院的DSM-IV型精神分裂症急性加重患者参加了这项为期6周，重复措施的前瞻性试验。第6周的平均+/- SD利培酮剂量为4.3 +/- 1.4 mg /天，每两周测量一次疗效，体重和耐受性。疗效通过阳性和阴性综合征量表（PANSS）和护士住院观察观察量表（NOSIE）进行评估。为了确定可能的预后因素对体重的影响，我们利用广义估计方程法来控制其他变量和受试者对重复评估的依赖性。结果：在调整了其他因素（包括基线体重）的影响后，治疗时间每增加1周，体重增加0.442千克（p <.0001）。将基线体重增加1 kg，体重增加减少了0.022 kg（p <.0001）。年龄每增加1年，体重就会减少0.052 kg（p <.001）。未分化亚型预测的体重比其他亚型高约0.9 kg（p <.05）。利培酮剂量每增加1毫克/天，体重就会增加0.084千克（p = .015）。响应者（PANSS总得分减少>或= 20％的人）的体重也平均增加了0.513千克（p = .007）。具体而言，PANSS总得分，PANSS阳性，PANSS阴性，PANSS认知得分和NOSIE得分每降低1分，体重分别平均增加0.029 kg，0.057 kg，0.079 kg，0.079 kg和0.035 kg（ p <或= .009）。其他变量没有重大影响。结论：结果表明，使用利培酮治疗的急性病患者，较低的初始体重，更年轻的年龄，未分化的亚型，较高的剂量和治疗反应（对于阳性，阴性，认知症状和社会功能）与更大的体重增加相关。需要进行更长时间的观察以及在其他人群中进行进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号